1. Ackermann M., Verleden S. E., Kuehnel M. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020; DOI: 10.1056/NEJMoa2015432. 2. De Rosa S., Spaccarotella C., Basso C. et al.; on behalf of Societa Italiana di Cardiologia and the CCU Academy investigators group. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J.2020; doi:10.1093/ eurheartj/ehaa409. 3. Guo T., Fan Y., Chen M. et all. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) // JAMA Cardiol. 2020; 5 (7): 811-818. 4. Kuster G. M., Pfister O., Burkard T. et al. SARS-CoV2: should inhibitors of the renin -angiotensin system be with drawn in patients with COVID-19? Eur Heart J.2020; 41: 1801-1803. 5. Lax S. F., Skok K., Zechner P. et al.Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series. Ann Intern Med. 2020; https://doi.org/10.7326/M20-2566 6. Shi S., Qin M., Shen B. et all. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China // JAMA Cardiol. 2020; 5 (7): 802-810. 7. Vaduganathan M., Vardeny O., Michel T. et al. Renin -Angiotensin -AldosteroneSystem Inhibitors in Patients with Covid-19. N Engl J Med. 2020; 382: 1653-1659. 8. Varga Z., Flammer A. J., Steiger P. Endothelial cell infection and endotheliitis inCOVID-19. Lancet. 2020; https://doi. org/10.1016/S0140-6736 (20) 30937-5